Clinical Trial Update: Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating pembrolizumab with cyclophosphamide and lenalidomide for relapsed multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• KEYTRUDA (PEMBROLIZUMAB)
• Revlimid (lenalidomide)

Snippet

Sponsor: University of Leeds | Conditions: Myeloma Multiple | Phase 1, Phase 2 | Status: WITHDRAWN